News & Events
-
September 1, 2018
Training on the use of technology to collect patient-reported outcome data electronically in clinical trials: best practice recommendations from the ePRO Consortium
Ly, JJ, Crescioni, M, Eremenco, S, Bodart, S, Donoso, M, Butler, AJ, et al. Training on the use of technology to collect patient-reported outcome data electronically in clinical trials: best practice recommendations from the ePRO Consortium. Therapeutic Innovation & Regulatory Science. 2018;1–10.... -
July 29, 2018
Perceived Burden of Completion of Patient-Reported Outcome Measures in Clinical Trials: Results of a Preliminary Study
Bodart, S B B, Crescioni, M E S,, Flood, E and on behalf of the ePRO C. Perceived Burden of Completion of Patient-Reported Outcome Measures in Clinical Trials: Results of a Preliminary Study. Therapeutic Innovation & Regulatory Science [Internet]. 2018 Jul 29.... -
June 1, 2018
Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018 Jun;18(6):675–83.
-
June 1, 2018
Mycobacterial biomaterials and resources for researchers
Hazbón MH, Rigouts L, Schito M, Ezewudo M, Kudo T, Itoh T, et al. Mycobacterial biomaterials and resources for researchers. Pathog Dis. 2018 Jun 1;76(4).
-
June 1, 2018
Informing the tolerability of cancer treatments using patient-reported outcome (PRO) measures: summary of an FDA and Critical Path Institute workshop
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero M, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O’Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the tolerability of cancer treatments using patient-reported outcome (PRO) measures: summary of an FDA and Critical Path Institute workshop. Value in Health 2018;21:742-747.